$VNRX

VolitionRx's COO, Gaetan Michel, disposed of 608 shares of common stock (VNRX) on September 28, 2026, at $0.2529 per share for tax purposes, leaving 12,232 shares owned.

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities Conversions of Note As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Globa

VolitionRx (VNRX) joins the €6.3M DETECSEPS Consortium in France to evaluate its Nu.Q® NETs assay for early sepsis detection. The project, funded by the French government, aims to improve patient outcomes and reduce healthcare burden. Volition provides the biomarker, while IDS France supplies the analyzer. Sepsis causes 21M deaths annually, with early detection crucial for treatment.

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities Conversions of Notes As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Glob

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027 Reduces Equity Overhang Henderson, Nevada, September 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-n

VolitionRx (VNRX) presented early-stage cancer detection data at ESMO MAP, showing 95% detection of stage I/II cancers using its Capture-Seq™ technology. The company targets a $36B market in early cancer detection and MRD, with plans to accelerate development and patent protection. Results showed no false positives in initial cohorts, with further studies underway.

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement . As previously reported, VolitionRx Limited (the “Company”) and Lind Global Asset Management XII LLC (“Lind”) entered into a Securities Purchase Agreement, dated May 15, 2025, as amended and restated on January 7, 2026 (the “

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management X

VolitionRx (VNRX) validated its Nu.Q NETs biomarker for sepsis, predicting mortality and kidney therapy needs. Published in Critical Care Medicine, the study found higher levels in septic shock, aiding risk stratification. The $0.34 stock fell 10.37%, amid a $2.8B market opportunity. The company completed a 1-for-20 reverse stock split on April 28, 2026.

VolitionRx reported 112% H1 revenue growth to $1.4M. The company highlighted progress in sepsis testing, lung cancer reimbursement, and cancer detection. It also announced a collaboration with Sysmex Corporation and active licensing discussions with global diagnostic leaders. Volition aims for a $5M milestone in veterinary diagnostics and a reimbursement submission in France by year-end.